Participants 47 159 6
patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
Participants 161 226 7
Experience of 36 patients treated in France in the RECORD-1 Trial
Participants 286 377 5
patients with metastatic renal cell carcinoma (mRCC) typically receive multiple treatments.
Participants 561 627 5
patients with disease progression after a TKI-everolimus sequence.
Participants 649 777 4
Data were reviewed for patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites.
Participants 921 972 4
Thirty-six patients received a TKI after everolimus
